Primary mediastinal large B-cell lymphoma: Outcome of a series of pediatric patients treated with high-dose methotrexate and cytarabine plus anti-CD20

Marta Pillon; E. Carraro; L. Mussolin; V. Conter; A. Tondo; M. Aricò; R. Mura; A. Sala; L. Vinti; S. Buffardi; P. Pierani; E. S.G. d'Amore; G. Basso

doi:10.1002/pbc.26855

Primary mediastinal large B-cell lymphoma: Outcome of a series of pediatric patients treated with high-dose methotrexate and cytarabine plus anti-CD20

Marta Pillon, E. Carraro, L. Mussolin, V. Conter, A. Tondo, M. Aricò, R. Mura, A. Sala, L. Vinti, S. Buffardi, P. Pierani, E. S.G. d'Amore, G. Basso

Research output: Contribution to journal › Article › peer-review

Abstract

Between 2007 and 2013, 13 children diagnosed with primary mediastinal large B-cell lymphoma (PMLBL) were treated according to a modified version of AIEOP (Associazione Italiana Ematologia Oncologia Pediatrica) LNH-97 protocol based on high-dose methotrexate, anthracyclines, and addition of anti-CD20. Ten patients achieved a continuous complete remission with front-line therapy. The overall 5-year survival was 91.7%, and event-free survival was 83.9%, with only one patient dying of progressive disease. Despite the few cases, these results demonstrate that this therapy, which includes anti-CD20, given in a multicenter setting, is feasible with acceptable toxicity in children with PMLBL.

Original language	English
Article number	e26855
Journal	Pediatric Blood and Cancer
Volume	65
Issue number	2
DOIs	https://doi.org/10.1002/pbc.26855
Publication status	Published - Oct 19 2017

Keywords

AIEOP LNH-97
childhood
NHL
PMLBL

ASJC Scopus subject areas

Pediatrics, Perinatology, and Child Health
Hematology
Oncology

Access to Document

10.1002/pbc.26855

Fingerprint Dive into the research topics of 'Primary mediastinal large B-cell lymphoma: Outcome of a series of pediatric patients treated with high-dose methotrexate and cytarabine plus anti-CD20'. Together they form a unique fingerprint.

Cite this

Pillon, M., Carraro, E., Mussolin, L., Conter, V., Tondo, A., Aricò, M., Mura, R., Sala, A., Vinti, L., Buffardi, S., Pierani, P., d'Amore, E. S. G., & Basso, G. (2017). Primary mediastinal large B-cell lymphoma: Outcome of a series of pediatric patients treated with high-dose methotrexate and cytarabine plus anti-CD20. Pediatric Blood and Cancer, 65(2), [e26855]. https://doi.org/10.1002/pbc.26855

Primary mediastinal large B-cell lymphoma : Outcome of a series of pediatric patients treated with high-dose methotrexate and cytarabine plus anti-CD20. / Pillon, Marta; Carraro, E.; Mussolin, L.; Conter, V.; Tondo, A.; Aricò, M.; Mura, R.; Sala, A.; Vinti, L.; Buffardi, S.; Pierani, P.; d'Amore, E. S.G.; Basso, G.

In: Pediatric Blood and Cancer, Vol. 65, No. 2, e26855, 19.10.2017.

Research output: Contribution to journal › Article › peer-review

Pillon, M, Carraro, E, Mussolin, L, Conter, V, Tondo, A, Aricò, M, Mura, R, Sala, A , Vinti, L, Buffardi, S, Pierani, P, d'Amore, ESG & Basso, G 2017, 'Primary mediastinal large B-cell lymphoma: Outcome of a series of pediatric patients treated with high-dose methotrexate and cytarabine plus anti-CD20', Pediatric Blood and Cancer, vol. 65, no. 2, e26855. https://doi.org/10.1002/pbc.26855

Pillon, Marta ; Carraro, E. ; Mussolin, L. ; Conter, V. ; Tondo, A. ; Aricò, M. ; Mura, R. ; Sala, A. ; Vinti, L. ; Buffardi, S. ; Pierani, P. ; d'Amore, E. S.G. ; Basso, G. / Primary mediastinal large B-cell lymphoma : Outcome of a series of pediatric patients treated with high-dose methotrexate and cytarabine plus anti-CD20. In: Pediatric Blood and Cancer. 2017 ; Vol. 65, No. 2.

@article{416d26a8d6004b23937fd2a5e18872fc,

title = "Primary mediastinal large B-cell lymphoma: Outcome of a series of pediatric patients treated with high-dose methotrexate and cytarabine plus anti-CD20",

abstract = "Between 2007 and 2013, 13 children diagnosed with primary mediastinal large B-cell lymphoma (PMLBL) were treated according to a modified version of AIEOP (Associazione Italiana Ematologia Oncologia Pediatrica) LNH-97 protocol based on high-dose methotrexate, anthracyclines, and addition of anti-CD20. Ten patients achieved a continuous complete remission with front-line therapy. The overall 5-year survival was 91.7%, and event-free survival was 83.9%, with only one patient dying of progressive disease. Despite the few cases, these results demonstrate that this therapy, which includes anti-CD20, given in a multicenter setting, is feasible with acceptable toxicity in children with PMLBL.",

keywords = "AIEOP LNH-97, childhood, NHL, PMLBL",

author = "Marta Pillon and E. Carraro and L. Mussolin and V. Conter and A. Tondo and M. Aric{\`o} and R. Mura and A. Sala and L. Vinti and S. Buffardi and P. Pierani and d'Amore, {E. S.G.} and G. Basso",

year = "2017",

month = oct,

day = "19",

doi = "10.1002/pbc.26855",

language = "English",

volume = "65",

journal = "Pediatric Blood and Cancer",

issn = "1545-5009",

publisher = "John Wiley and Sons Inc.",

number = "2",

}

TY - JOUR

T1 - Primary mediastinal large B-cell lymphoma

T2 - Outcome of a series of pediatric patients treated with high-dose methotrexate and cytarabine plus anti-CD20

AU - Pillon, Marta

AU - Carraro, E.

AU - Mussolin, L.

AU - Conter, V.

AU - Tondo, A.

AU - Aricò, M.

AU - Mura, R.

AU - Sala, A.

AU - Vinti, L.

AU - Buffardi, S.

AU - Pierani, P.

AU - d'Amore, E. S.G.

AU - Basso, G.

PY - 2017/10/19

Y1 - 2017/10/19

N2 - Between 2007 and 2013, 13 children diagnosed with primary mediastinal large B-cell lymphoma (PMLBL) were treated according to a modified version of AIEOP (Associazione Italiana Ematologia Oncologia Pediatrica) LNH-97 protocol based on high-dose methotrexate, anthracyclines, and addition of anti-CD20. Ten patients achieved a continuous complete remission with front-line therapy. The overall 5-year survival was 91.7%, and event-free survival was 83.9%, with only one patient dying of progressive disease. Despite the few cases, these results demonstrate that this therapy, which includes anti-CD20, given in a multicenter setting, is feasible with acceptable toxicity in children with PMLBL.

AB - Between 2007 and 2013, 13 children diagnosed with primary mediastinal large B-cell lymphoma (PMLBL) were treated according to a modified version of AIEOP (Associazione Italiana Ematologia Oncologia Pediatrica) LNH-97 protocol based on high-dose methotrexate, anthracyclines, and addition of anti-CD20. Ten patients achieved a continuous complete remission with front-line therapy. The overall 5-year survival was 91.7%, and event-free survival was 83.9%, with only one patient dying of progressive disease. Despite the few cases, these results demonstrate that this therapy, which includes anti-CD20, given in a multicenter setting, is feasible with acceptable toxicity in children with PMLBL.

KW - AIEOP LNH-97

KW - childhood

KW - NHL

KW - PMLBL

UR - http://www.scopus.com/inward/record.url?scp=85038574577&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85038574577&partnerID=8YFLogxK

U2 - 10.1002/pbc.26855

DO - 10.1002/pbc.26855

M3 - Article

C2 - 29049862

AN - SCOPUS:85038574577

VL - 65

JO - Pediatric Blood and Cancer

JF - Pediatric Blood and Cancer

SN - 1545-5009

IS - 2

M1 - e26855

ER -